Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.
Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.
Kura Oncology, Inc. Chief Legal Officer Teresa Brophy Bair sold 8,442 common shares at $10.4973 per share on September 28, 2026, leaving her with 187,002 shares held directly. The sale was reported as a sell-to-cover for taxes associated with vesting 1/6th of the shares underlying performance-based restricted stock units granted May 31, 2023. The transaction was reported under a Rule 10b5-1 trading plan.
Kura Oncology, Inc. Chief Operating Officer Kathleen Ford reported direct sales of 6,906 common shares on September 28, 2026, at $10.4973 per share and 3,668 shares on September 29 at a weighted-average $10.7516 per share. The September 28 sale was a sell-to-cover for taxes associated with vesting 1/6th of the underlying shares of performance-based restricted stock units; the September 29 shares were acquired upon vesting of performance restricted stock units on September 27. The sales were effected under a Rule 10b5-1 trading plan adopted May 29, 2026.
Kura Oncology, Inc.'s Chief Medical Officer, Mollie Leoni, reported direct sales of 12,448 common shares at $10.4973 per share on September 28, 2026, and 28,802 shares at a weighted average $10.7481 per share on September 29, 2026. The September 28 sale covered taxes tied to vesting one-sixth of the underlying performance-based restricted stock units after a development milestone was determined to have been met on September 27, 2026. The September 29 sale was made under a Rule 10b5-1 trading plan adopted on March 19, 2026; trades ranged from $10.53 to $10.89.
Kura Oncology, Inc. SVP, Finance & Accounting Thomas James Doyle sold 4,607 shares of common stock on September 28, 2026, at $10.4972 per share in a tax sell-to-cover tied to vesting of 1/6th of the underlying performance-based restricted stock units. After the sale, he directly held 142,428 shares; a separate indirect holding lists 500 shares through his spouse’s 401(k). The direct post-transaction total includes 1,868 shares acquired on May 17, 2026, under the Employee Stock Purchase Plan. No Rule 10b5-1 plan is reported.
Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl reported selling 32,450 shares of common stock in three transactions on September 28 and 29, 2026. He sold 9,020 shares at $10.4973 per share on September 28 as a sell-to-cover for taxes associated with RSU vesting. He also sold 8,000 shares on September 28 at a weighted-average price of $10.5622 and 15,430 shares on September 29 at a weighted-average price of $10.7487. The latter two sales were made under a Rule 10b5-1 trading plan adopted May 22, 2026.
Kura Oncology, Inc. (KURA) Officer Brian Powl reported a proposed sale of 15,430 common shares, with an aggregate market value of $163,712.30 and an approximate sale date of September 29, 2026. The notice also lists prior sales during the past three months: 8,000 shares on September 28, 2026, 9,020 shares on September 27, 2026, and 4,345 shares on August 21, 2026.
Kura Oncology, Inc. (KURA) officer Mollie Vanessa Leoni gave notice of a proposed sale of 28,802 common shares, with an aggregate market value of $305,589.22 and an approximate sale date of September 29, 2026, through Morgan Stanley Smith Barney LLC. The securities detail identifies performance stock units from the issuer dated September 27, 2026. Leoni also reported selling 12,448 common shares during the preceding three months, with an aggregate market value of $130,670.01.
Kura Oncology, Inc. officer Kathleen Ford gave notice of a proposed sale of 3,668 common shares, with a reported aggregate market value of $38,917.48. Morgan Stanley Smith Barney LLC is named as broker, and the approximate sale date is September 29, 2026. The securities are listed as acquired from the issuer as Performance Stock Units on September 27, 2026. The past-three-month sales section lists 6,906 common shares sold for $72,494.35 on September 27, 2026.
Kura Oncology, Inc. officer Brian T. Powl reported an intended sale of 9,020 common shares, with an aggregate market value of $97,055.20 and a planned sale date of September 28, 2026. The shares are listed as acquired from the issuer through restricted stock units on September 27, 2026. Kura Oncology had 91,869,597 shares outstanding as of September 28, 2026.
Sales listed for Powl during the preceding three months included 4,345 restricted stock units on August 21, 2026, with a reported value of $51,663.26, and 8,000 on September 28, 2026, with a reported value of $84,497.61.
Mollie Leoni, an officer of Kura Oncology, Inc. (KURA), reported a planned sale of 12,448 common shares, with an aggregate market value of $133,940.48 and an approximate sale date of September 28, 2026. Morgan Stanley Smith Barney LLC is listed as broker. The notice lists the shares as acquired from the issuer in a PSU transaction on September 27, 2026. Teresa Bair signed as attorney-in-fact for Mollie Leoni.